Protagonist Therapeutics Inc (PTGX) stock news · rev $46.0M
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
This PTGX news page leads with what Protagonist Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for PTGX yet. We will not pad this page with generic market recap.
Latest reported PTGX revenue for 2025-12-31 was $46.0M. Net income was -$130.1M. Revenue was down 89.4% from 2024-12-31 to 2025-12-31. PTGX currently screens at market cap $7.25B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the PTGX stock page; for the tape open the quote page.
PTGX stock news FAQ
What are PTGX's latest revenue and net income?
Latest cached Protagonist Therapeutics Inc (PTGX) revenue for Dec 31, 2025 was $46.0M. Net income was -$130.1M. Statements: https://lician.com/financials/ptgx
How did PTGX revenue change from the prior cached period?
Cached Protagonist Therapeutics Inc (PTGX) revenue was down 89.4% from $434.4M (Dec 31, 2024) to $46.0M (Dec 31, 2025). Statements: https://lician.com/financials/ptgx
What is PTGX's market cap?
Protagonist Therapeutics Inc (PTGX) market cap is $7.25B on the latest cached fundamentals snapshot.
What kind of company is PTGX?
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Where is PTGX stock news listed?
Cached stock news for Protagonist Therapeutics Inc (PTGX) is listed at https://lician.com/news/ptgx. Filings: https://lician.com/sec/ptgx
Not investment advice.